{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T17:37:29Z","timestamp":1778693849946,"version":"3.51.4"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,3,15]],"date-time":"2019-03-15T00:00:00Z","timestamp":1552608000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2019,3,15]],"date-time":"2019-03-15T00:00:00Z","timestamp":1552608000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001655","name":"Deutscher Akademischer Austauschdienst","doi-asserted-by":"publisher","award":["(57129429)"],"award-info":[{"award-number":["(57129429)"]}],"id":[{"id":"10.13039\/501100001655","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["INST 268\/281-1 FUGG"],"award-info":[{"award-number":["INST 268\/281-1 FUGG"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s10637-019-00752-0","type":"journal-article","created":{"date-parts":[[2019,3,15]],"date-time":"2019-03-15T21:06:07Z","timestamp":1552683967000},"page":"1-9","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Identification of inhibitors of the polo-box domain of polo-like kinase 1 from natural and semisynthetic compounds"],"prefix":"10.1007","volume":"38","author":[{"given":"Sara","family":"Abdelfatah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edmond","family":"Fleischer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anette","family":"Klinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent Kam Wai","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2637-1681","authenticated-orcid":false,"given":"Thomas","family":"Efferth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,3,15]]},"reference":[{"key":"752_CR1","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1038\/sj.onc.1208617","volume":"24","author":"MATM Van Vugt","year":"2005","unstructured":"Van Vugt MATM, Medema RH (2005) Getting in and out of mitosis with polo-like kinase-1. Oncogene 24:2844\u20132859","journal-title":"Oncogene"},{"key":"752_CR2","doi-asserted-by":"crossref","first-page":"7937","DOI":"10.1073\/pnas.0402442101","volume":"101","author":"Y Moshe","year":"2004","unstructured":"Moshe Y, Boulaire J, Pagano M, Hershko A (2004) Role of polo-like kinase in the degradation of early mitotic inhibitor 1, a regulator of the anaphase promoting complex\/cyclosome. Proc Natl Acad Sci U S A 101:7937\u20137942","journal-title":"Proc Natl Acad Sci U S A"},{"key":"752_CR3","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/sj.onc.1208280","volume":"24","author":"DM Lowery","year":"2005","unstructured":"Lowery DM, Lim D, Yaffe MB (2005) Structure and function of polo-like kinases. Oncogene 24:248\u2013259","journal-title":"Oncogene"},{"key":"752_CR4","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1126\/science.1157425","volume":"320","author":"A Seki","year":"2008","unstructured":"Seki A, Coppinger J a, Jang C-Y et al (2008) Bora and the kinase Aurora a cooperatively activate the kinase Plk1 and control mitotic entry. Science 320:1655\u20131658","journal-title":"Science"},{"key":"752_CR5","doi-asserted-by":"crossref","unstructured":"Ohkura H, Hagan IM, Glover DM (1995) The conserved Schizosaccharomyces pombe kinase plol , required to form a bipolar. Genes Dev:1059\u20131073","DOI":"10.1101\/gad.9.9.1059"},{"key":"752_CR6","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1083\/jcb.135.6.1701","volume":"135","author":"HA Lane","year":"1996","unstructured":"Lane HA, Nigg EA (1996) Antibody microinjection reveals an essential role for human polo-like kinase 1 (Plk1) in the functional maturation of mitotic centrosomes. J Cell Biol 135:1701\u20131713","journal-title":"J Cell Biol"},{"key":"752_CR7","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S0955-0674(98)80121-X","volume":"10","author":"EA Nigg","year":"1998","unstructured":"Nigg EA (1998) Polo-like kinases: positive regulators of cell division from start to finish. Curr Opin Cell Biol 10:776\u2013783","journal-title":"Curr Opin Cell Biol"},{"key":"752_CR8","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.18632\/oncotarget.1861","volume":"5","author":"M Sanhaji","year":"2014","unstructured":"Sanhaji M, Ritter A, Belsham HR et al (2014) Polo-like kinase 1 regulates the stability of the mitotic centromere-associated kinesin in mitosis. Oncotarget 5:3130\u20133144","journal-title":"Oncotarget"},{"key":"752_CR9","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1349-7006.2006.00170.x","volume":"97","author":"W Weichert","year":"2006","unstructured":"Weichert W, Ullrich A, Schmidt M et al (2006) Expression patterns of polo-like kinase 1 in human gastric cancer. Cancer Sci 97:271\u2013276","journal-title":"Cancer Sci"},{"key":"752_CR10","volume":"37","author":"H Li","year":"2017","unstructured":"Li H, Wang H, Sun Z et al (2017) The clinical and prognostic value of polo-like kinase 1 in lung squamous cell carcinoma patients: immunohistochemical analysis. Biosci Rep 37:BSR20170852","journal-title":"Biosci Rep"},{"key":"752_CR11","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1634\/theoncologist.2009-0010","volume":"14","author":"P Sch\u00f6ffski","year":"2009","unstructured":"Sch\u00f6ffski P (2009) Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist 14:559\u2013570","journal-title":"Oncologist"},{"key":"752_CR12","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1002\/cbic.201500580","volume":"17","author":"A Berg","year":"2016","unstructured":"Berg A, Berg T (2016) Inhibitors of the polo-box domain of polo-like kinase 1. Chem Bio Chem 17:650\u2013656","journal-title":"Chem Bio Chem"},{"key":"752_CR13","doi-asserted-by":"crossref","first-page":"3094","DOI":"10.1158\/1078-0432.CCR-08-2445","volume":"15","author":"D Rudolph","year":"2009","unstructured":"Rudolph D, Steegmaier M, Hoffmann M et al (2009) BI 6727, a polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity. Clin Cancer Res 15:3094\u20133102","journal-title":"Clin Cancer Res"},{"key":"752_CR14","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1038\/cr.2014.86","volume":"24","author":"M Raab","year":"2014","unstructured":"Raab M, Pachl F, Kramer A et al (2014) Quantitative chemical proteomics reveals a Plk1 inhibitor-compromised cell death pathway in human cells. Cell Res 24:1141\u20131145","journal-title":"Cell Res"},{"key":"752_CR15","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.tranon.2015.03.010","volume":"8","author":"X Liu","year":"2015","unstructured":"Liu X (2015) Targeting polo-like kinases: a promising therapeutic approach for Cancer treatment. Transl Oncol 8:185\u2013195","journal-title":"Transl Oncol"},{"key":"752_CR16","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1073\/pnas.0609131104","volume":"104","author":"B Garc\u00eda-Alvarez","year":"2007","unstructured":"Garc\u00eda-Alvarez B, de C\u00e1rcer G, Iba\u00f1ez S et al (2007) Molecular and structural basis of polo-like kinase 1 substrate recognition: implications in centrosomal localization. Proc Natl Acad Sci U S A 104:3107\u20133112","journal-title":"Proc Natl Acad Sci U S A"},{"key":"752_CR17","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1021\/cb200469a","volume":"7","author":"F Liu","year":"2012","unstructured":"Liu F, Park JE, Qian WJ et al (2012) Identification of high affinity polo-like kinase 1 (Plk1) polo-box domain binding peptides using oxime-based diversification. ACS Chem Biol 7:805\u2013810","journal-title":"ACS Chem Biol"},{"key":"752_CR18","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0092-8674(03)00725-6","volume":"115","author":"AEH Elia","year":"2003","unstructured":"Elia AEH, Rellos P, Haire LF et al (2003) The molecular basis for phosphodependent substrate targeting and regulation of Plks by the polo-box domain. Cell 115:83\u201395","journal-title":"Cell"},{"key":"752_CR19","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nrc723","volume":"2","author":"J Mann","year":"2002","unstructured":"Mann J (2002) Natural products in cancer chemotherapy: past, present and future. Nat Rev Cancer 2:143\u2013148","journal-title":"Nat Rev Cancer"},{"key":"752_CR20","first-page":"1390","volume":"23","author":"IS Johnson","year":"1963","unstructured":"Johnson IS, Armstrong JG, Gorman M, Burnett JP (1963) The Vinca alkaloids: a new class of oncolytic agents. Cancer Res 23:1390\u20131427","journal-title":"Cancer Res"},{"key":"752_CR21","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/j.1751-7915.2010.00221.x","volume":"4","author":"AL Demain","year":"2011","unstructured":"Demain AL, Vaishnav P (2011) Natural products for cancer chemotherapy. Microb Biotechnol 4:687\u2013699","journal-title":"Microb Biotechnol"},{"key":"752_CR22","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1021\/cb3004379","volume":"8","author":"Z Yin","year":"2013","unstructured":"Yin Z, Song Y, Rehse PH (2013) Thymoquinone blocks pSer\/pThr recognition by plk1 polo-box domain as a phosohate mimic. ACS Chem Biol 8:303\u2013308","journal-title":"ACS Chem Biol"},{"key":"752_CR23","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1007\/s13277-013-0764-5","volume":"34","author":"G Zhang","year":"2013","unstructured":"Zhang G, Zhang Z, Liu Z (2013) Scytonemin inhibits cell proliferation and arrests cell cycle through downregulating Plk1 activity in multiple myeloma cells. Tumor Biol 34:2241\u20132247","journal-title":"Tumor Biol"},{"key":"752_CR24","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.bcp.2017.10.008","volume":"146","author":"S Hamdoun","year":"2017","unstructured":"Hamdoun S, Fleischer E, Klinger A, Efferth T (2017) Lawsone derivatives target the Wnt\/\u03b2-catenin signaling pathway in multidrug-resistant acute lymphoblastic leukemia cells. Biochem Pharmacol 146:63\u201373","journal-title":"Biochem Pharmacol"},{"key":"752_CR25","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.phymed.2014.07.011","volume":"21","author":"M Saeed","year":"2014","unstructured":"Saeed M, Kuete V, Kadioglu O et al (2014) Cytotoxicity of the bisphenolic honokiol from Magnolia officinalis against multiple drug-resistant tumor cells as determined by pharmacogenomics and molecular docking. Phytomedicine 21:1525\u20131533","journal-title":"Phytomedicine"},{"key":"752_CR26","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.phymed.2017.07.010","volume":"33","author":"V Kuete","year":"2017","unstructured":"Kuete V, Mbaveng AT, Sandjo LP et al (2017) Cytotoxicity and mode of action of a naturally occurring naphthoquinone, 2-acetyl-7-methoxynaphtho[2,3-b]furan-4,9-quinone towards multi-factorial drug-resistant cancer cells. Phytomedicine 33:62\u201368","journal-title":"Phytomedicine"},{"key":"752_CR27","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.chembiol.2008.03.013","volume":"15","author":"W Reindl","year":"2008","unstructured":"Reindl W, Yuan J, Kr\u00e4mer A et al (2008) Inhibition of polo-like kinase 1 by blocking polo-box domain-dependent protein-protein interactions. Chem Biol 15:459\u2013466","journal-title":"Chem Biol"},{"key":"752_CR28","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.ab.2008.08.014","volume":"383","author":"W Reindl","year":"2008","unstructured":"Reindl W, Strebhardt K, Berg T (2008) A high-throughput assay based on fluorescence polarization for inhibitors of the polo-box domain of polo-like kinase 1. Anal Biochem 383:205\u2013209","journal-title":"Anal Biochem"},{"key":"752_CR29","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ab.2009.08.031","volume":"395","author":"W Reindl","year":"2009","unstructured":"Reindl W, Gr\u00e4ber M, Strebhardt K, Berg T (2009) Development of high-throughput assays based on fluorescence polarization for inhibitors of the polo-box domains of polo-like kinases 2 and 3. Anal Biochem 395:189\u2013194","journal-title":"Anal Biochem"},{"key":"752_CR30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0101405","volume":"9","author":"S Sakkiah","year":"2014","unstructured":"Sakkiah S, Senese S, Yang Q et al (2014) Dynamic and multi-pharmacophore modeling for designing polo-box domain inhibitors. PLoS One 9:1\u20139","journal-title":"PLoS One"},{"key":"752_CR31","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1021\/acschembio.5b00565","volume":"10","author":"A Scharow","year":"2015","unstructured":"Scharow A, Raab M, Saxena K et al (2015) Optimized Plk1 PBD inhibitors based on Poloxin induce mitotic arrest and apoptosis in tumor cells. ACS Chem Biol 10:2570\u20132579","journal-title":"ACS Chem Biol"},{"key":"752_CR32","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nrd2907","volume":"8","author":"S Lapenna","year":"2009","unstructured":"Lapenna S, Giordano A (2009) Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov 8:547\u2013566","journal-title":"Nat Rev Drug Discov"},{"key":"752_CR33","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/nrd3184","volume":"9","author":"K Strebhardt","year":"2010","unstructured":"Strebhardt K (2010) Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy. Nat Rev Drug Discov 9:643\u2013660","journal-title":"Nat Rev Drug Discov"},{"key":"752_CR34","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nrc1841","volume":"6","author":"K Strebhardt","year":"2006","unstructured":"Strebhardt K, Ullrich A (2006) Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer 6:321\u2013330","journal-title":"Nat Rev Cancer"},{"key":"752_CR35","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1128\/MCB.26.6.2093-2108.2006","volume":"26","author":"X Liu","year":"2006","unstructured":"Liu X, Lei M, Erikson RL (2006) Normal cells , but not Cancer cells , survive severe Plk1 depletion. Mol Cell Biol 26:2093\u20132108","journal-title":"Mol Cell Biol"},{"key":"752_CR36","doi-asserted-by":"crossref","first-page":"3935","DOI":"10.1038\/onc.2008.36","volume":"27","author":"M Lei","year":"2008","unstructured":"Lei M, Erikson RL (2008) Plk1 depletion in nontransformed diploid cells activates the DNA-damage checkpoint. Oncogene 27:3935\u20133943","journal-title":"Oncogene"},{"key":"752_CR37","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/j.ajpath.2011.06.031","volume":"179","author":"J Yuan","year":"2011","unstructured":"Yuan J, Sanhaji M, Krmer A et al (2011) Polo-box domain inhibitor poloxin activates the spindle assembly checkpoint and inhibits tumor growth in vivo. Am J Pathol 179:2091\u20132099","journal-title":"Am J Pathol"},{"key":"752_CR38","doi-asserted-by":"crossref","first-page":"7089","DOI":"10.1021\/acs.jmedchem.6b00261","volume":"59","author":"T Qin","year":"2016","unstructured":"Qin T, Chen F, Zhuo X et al (2016) Discovery of novel polo-like kinase 1 polo-box domain inhibitors to induce mitotic arrest in tumor cells. J Med Chem 59:7089\u20137096","journal-title":"J Med Chem"},{"key":"752_CR39","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/cmdc.201402284","volume":"10","author":"HM Shan","year":"2015","unstructured":"Shan HM, Shi Y, Quan J (2015) Identification of green tea Catechins as potent inhibitors of the polo-box domain of polo-like kinase 1. ChemMedChem 10:158\u2013163","journal-title":"ChemMedChem"},{"key":"752_CR40","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.18632\/oncotarget.13603","volume":"8","author":"Y Chen","year":"2016","unstructured":"Chen Y, Zhang J, Li D et al (2016) Identification of a novel polo-like kinase 1 inhibitor that specifically blocks the functions of polo-box domain. Oncotarget 8:1234\u20131246","journal-title":"Oncotarget"},{"key":"752_CR41","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1182\/blood-2005-03-1194","volume":"107","author":"N Syed","year":"2006","unstructured":"Syed N, Smith P, Sullivan A et al (2006) Transcriptional silencing of polo-like kinase 2 ( SNK \/ PLK2 ) is a frequent event in B-cell malignancies. Blood 107:250\u2013256","journal-title":"Blood"},{"key":"752_CR42","doi-asserted-by":"crossref","first-page":"4077","DOI":"10.1158\/0008-5472.CAN-07-6182","volume":"68","author":"Y Yang","year":"2008","unstructured":"Yang Y, Bai J, Shen R et al (2008) Polo-like kinase 3 functions as a tumor suppressor and is a negative regulator of hypoxia-inducible factor-1?? Under hypoxic conditions. Cancer Res 68:4077\u20134085","journal-title":"Cancer Res"},{"key":"752_CR43","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/MPH.0b013e3181a974b3","volume":"31","author":"J Bro\u017cek","year":"2009","unstructured":"Bro\u017cek J, Bryl E, P\u0142oszy\u0144ska A et al (2009) P-glycoprotein activity predicts outcome in childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol 31:493\u2013499","journal-title":"J Pediatr Hematol Oncol"},{"key":"752_CR44","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1046\/j.1365-2141.1999.01378.x","volume":"105","author":"C Dhooge","year":"1999","unstructured":"Dhooge C, De Moerloose B, Laureys G et al (1999) P-glycoprotein is an independent prognostic factor predicting relapse in childhood acute lymphoblastic leukaemia: results of a 6-year prospective study. Br J Haematol 105:676\u2013683","journal-title":"Br J Haematol"},{"key":"752_CR45","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.1021\/acs.molpharmaceut.5b00312","volume":"12","author":"CP Wu","year":"2015","unstructured":"Wu CP, Hsieh CH, Hsiao SH et al (2015) Human ATP-binding cassette transporter ABCB1 confers resistance to Volasertib (BI 6727), a selective inhibitor of polo-like kinase 1. Mol Pharm 12:3885\u20133895","journal-title":"Mol Pharm"},{"key":"752_CR46","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1158\/1078-0432.CCR-14-2890","volume":"22","author":"R Ferrarotto","year":"2016","unstructured":"Ferrarotto R, Goonatilake R, Young Yoo S et al (2016) Epithelial-mesenchymal transition predicts polo-like kinase 1 inhibitor-mediated apoptosis in non-small cell lung Cancer. Clin Cancer Res 22:1674\u20131686","journal-title":"Clin Cancer Res"},{"key":"752_CR47","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.molcel.2006.06.016","volume":"23","author":"N Mailand","year":"2006","unstructured":"Mailand N, Bekker-Jensen S, Bartek J, Lukas J (2006) Destruction of Claspin by SCFbTrCP restrains Chk1 activation and facilitates recovery from genotoxic stress. Mol Cell 23:307\u2013318","journal-title":"Mol Cell"},{"key":"752_CR48","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1101\/gad.436007","volume":"21","author":"S Elowe","year":"2007","unstructured":"Elowe S, H\u00fcmmer S, Uldschmid A et al (2007) On BubR1 regulates the stability of kinetochore \u2013 microtubule interactions. Genes Dev 21:2205\u20132219","journal-title":"Genes Dev"},{"key":"752_CR49","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1038\/nchembio826","volume":"2","author":"U Peters","year":"2006","unstructured":"Peters U, Cherian J, Kim JH et al (2006) Probing cell-division phenotype space and polo-like kinase function using small molecules. Nat Chem Biol 2:618\u2013626","journal-title":"Nat Chem Biol"},{"issue":"80","key":"752_CR50","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1126\/science.1079079","volume":"299","author":"AEH Elia","year":"2003","unstructured":"Elia AEH (2003) Proteomic screen finds pSer\/pThr-binding domain localizing Plk1 to mitotic substrates. Science 299(80):1228\u20131231","journal-title":"Science"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-019-00752-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-019-00752-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-019-00752-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T18:40:46Z","timestamp":1678560046000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-019-00752-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,15]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["752"],"URL":"https:\/\/doi.org\/10.1007\/s10637-019-00752-0","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,15]]},"assertion":[{"value":"8 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Sara Abdelfatah declares that she has no conflict of interest. Edmond Fleisher declares that he has no conflict of interest. Annette Klinger declares that she has no conflict of interest. Vincent K. W. Wong declares that he has no conflict of interest. Thomas Efferth declares that he has no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"For this type of study, formal consent is not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}